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The creation and characterisation of a National
Compound Collection: the Royal Society of
Chemistry pilot†‡
David M. Andrews,§*a Laura M. Broad,b Paul J. Edwards,c David N. A. Fox,a
Timothy Gallagher,b Stephen L. Garland,d Richard Kidda and Joseph B. Sweeneye
We present a summary of the National Compound Collection (NCC) pilot; which harvested chemical
structure data from 746 publicly-available PhD theses to create an enhanced database of diverse and
interesting (largely organic) molecular entities. The database comprised 75 000 structure entries, of
which 70% were new to ChemSpider at the time of upload. The dataset was evaluated for structural
uniqueness by twelve external drug discovery groups from the pharmaceutical, biotech, academic and
not-for-proﬁt sectors. These partners generated data reported here comparing the NCC pilot with their
in-house compound collections. The proportion of NCC structures considered to be useful for drug
discovery ranged from 5–80% depending on the strictness of the ﬁlters used; most interestingly from
a drug discovery standpoint 13k NCC compounds (18% of the NCC) passed the ﬁlters and were of
good diversity. These compounds are quite diﬀerent from those that are already present in the screening
collections but not so diﬀerent that they are no longer considered to be drug-like. In general, the drug
discovery teams would consider these compounds to be high value molecules for inclusion in their
screening collections. This pilot addressed the potential value of unpublished data and explored the
practicalities of large-scale data extraction, to inform both retrospective and prospective extraction of
chemical data from theses.
Introduction
Arguably the most important output of UK chemistry depart-
ments is the cohort of PhD students that have been trained in
research methods and experimental techniques; it has been
estimated that more than $20Bn has been contributed to the
global pharmaceutical sector by UK-funded/based PhDs.1 All of
those students produce a thesis andmany of those theses contain
new chemical entities or new (and oen better) ways to synthe-
sise important chemical entities, with a strict requirement of the
degree being that compounds are adequately and appropriately
characterised. While a good deal of a PhD student’s work is
published, any practicing academic knows that there is oen also
a signicant body of results within a thesis that, because they
didn’t deliver “the research goal”, remain unpublished in the
primary literature. This body of unpublished “big data”
frequently includes novel compounds, experimental data which
will also meet the degree requirements of quality and charac-
terisation. These inaccessible and not computer-searchable
“hidden data” represent a valuable and untapped resource for
chemists and indeed the wider molecule-using research
community.
It is also important to appreciate that the process of a PhD
degree necessarily results in the publication of the thesis, so
theses are free-standing scientic documents in their own right,
which are available, possibly subject to a period of embargo and
with varying accessibility, once the degree requirements have
been met and the nal copy has been submitted.
We have carried out a pilot study, the goal of which was to
evaluate the potential and realise the value of these hidden data
by harvesting chemical structure information from PhD theses
to create an enhanced database of novel and interesting
molecular entities. It was important that the theses made
available were published (and consequently within the public
domain) and not subject to IP issues, in that journal
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publications and any patent claims had already been made. It
was also apparent that an ideal vehicle for structural data
deposition, dissemination and retrieval was the Royal Society of
Chemistry (RSC)’s ChemSpider,2 already a validated chemical
structure database. We envisaged such a database also as being
able to (i) benet from harvesting a wealth of “legacy” data – i.e.
from many older theses – and (ii) provide a means to capture
new theses as these are produced/published going into the
future. The latter would then provide a mechanism for constant
refreshing and extending a wide-ranging and comprehensive
“tangible” database with new structural entities. In this context,
a tangible database is a database of compounds which are
known to have been synthesised; by comparison a “virtual”
database contains the structures of compounds which could be
made (cf. Hann3). In contrast, a “physical” collection refers to
a situation in which compounds exist as physical samples
available for screening. While a tangible collection has signi-
cant advantages over virtual libraries, it is widely recognised
that eventually, access to a physical sample is required in order
to conrm activity and initiate a follow-up programme. Since
the completion of this work, Research Councils UK (RCUK), on
behalf of the UK Open Research Data Forum, published a dra
Concordat on Open Research Data, which sets out both prin-
ciples and expectations of good practice in publishing research
data openly4 (see Box 1). These principles are in good alignment
to many of the issues and opportunities we identied during the
course of this pilot.
We also saw, given the rapidly increasing power of in silico
tools, that there was an exciting opportunity to lter a struc-
tural database in order to prioritise and select a subset
of molecules that could then be targeted for re-synthesis.
Ultimately, this could provide a starting point for a separate
physical National Compound Collection aligned to an in
silico tangible collection, the pilot study for which is described
here.
We envisaged any database (be it tangible or physical) as
a widely applicable resource that should be of use to any sector
of “molecule users”, where in particular the tangible compo-
nent (i.e. the in silico element) could be triaged/ltered in
a bespoke manner or not at all according to the demands
associated with a particular end-user.5
We also recognised that there was a variety of constituen-
cies that needed to engage to enable this project to establish
the credibility and momentum necessary for sustained
success. Stakeholders included “producers” (academic chem-
istry groupings involved in synthesis), end-users (both
academic and industry, from SMEs to multinationals and
across various end-user sectors), and associate industry
players (e.g. companies involved in contract synthesis, devel-
opment or use of new in silico tools, collection and curation of
substantial collections). The support of research funders was
also seen as important since EPSRC funds some 40% of UK
chemistry PhDs and EPSRC, BBSRC, MRC and the Wellcome
Trust all fund a wide range of “molecule users”. Gaining input
from academic institutions was seen as essential since they are
the primary source of structural data and oen Intellectual
Property owners. Finally, professional and other bodies (e.g.
RSC, British Library) are able to bring various other critical
elements to the project. This includes a key role (e.g. for RSC)
in coordinating the engagement of these various “interested
parties”.
Goals of the pilot
Goal 1: to explore the processes and procedures required to
extract structural data from academic theses, to inform
a future national scale activity
We used a manual data extraction approach for the pilot study,
following initial experimentation with the use of chemistry
intelligent Optical Character Recognition (OCR) soware.6
Box 1: the ten concordat principles
(1) Open access to research data is an enabler of high quality research, a facilitator of innovation and safeguards good
research practice.
(2) Good data management is fundamental to all stages of the research process and should be established at the outset.
(3) Data must be curated so that they are accessible, discoverable and useable.
(4) Open access to research data carries a signicant cost, which should be respected by all parties.
(5) There are sound reasons why the openness of research data may need to be restricted but any restrictions must be
justied and justiable.
(6) The right of the creators of research data to reasonable rst use is recognised.
(7) Use of others’ data should always conform to legal, ethical and regulatory frameworks including appropriate
acknowledgement.
(8) Data supporting publications should be accessible by the publication date and should be in a citeable form.
(9) Support for the development of appropriate data skills is recognised as a responsibility for all stakeholders.
(10) Regular reviews of progress towards open access to research data should be undertaken.
Chem. Sci. This journal is © The Royal Society of Chemistry 2016
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Challenges around accessibility of digital copies copyright (we
exercised caution in this regard) together with the necessary
costs of licences, training and quality assurance of the accuracy
of the data collected suggested that a national scale activity
would require industry standard mixed approaches already
employed by commercial database providers. Work carried out
by the British Library examined the accessibility of the theses
across institutions, in terms of availability of digital copies and
the licensing of theses by diﬀerent institutions. The implica-
tions of the recent copyright exemption for text and data mining
in the context of the project were also used to inform this pilot
and the EThOS (e-theses Online Service http://ethos.bl.uk/
About.do) digital collection.
Goal 2: to demonstrate an ability to collect and collate
a database of structural and bibliographic information within
RSC’s ChemSpider
ChemSpider is a free-to-access resource developed with RSC
that is well-suited for hosting data of the type we would deposit,
especially as a demonstrator for the pilot. Modications were
required to provide a specialist deposition interface to include
thesis-specic details. Deposition and export tools provided an
easy method for the data collectors to remotely update and
publish the collected data. The pilot data cleared for release are
available through ChemSpider, and as a Creative Commons
CC0 licensed download. The CC0 licence has been applied to
this data in line with the principles applied to linked data by
BioMed Central7 and Nature Publishing Group.8,9
Goal 3: to demonstrate the searchable nature of this tangible
database using customised lters and specically to exploit
the database via in silico screening against a series of
“societally important” proteins
Linked to this was the parallel use of the similarly-sized French-
based compound collection.10 The latter is an academically-
derived physical collection that has been screened for biosci-
ence application. We applied parallel in silico screening of the
two collections to a series of protein structures using the Bristol
University Docking Engine (BUDE).11 The French collection
provided us with the opportunity to source, screen and validate
the principles and methodology of the in silico screening and
served, consequently, as a proxy for a “physical” equivalent to
our pilot data collection. The outcome of this part of the study,
which involved in silico assessment and then physical screening
using the relevant French hits against some 30 diﬀerent protein
targets, will be the subject of a separate publication and will not
be covered in any more depth here.
Goal 4: assessment by external bioscience/pharma partners to
evaluate the “uniqueness” and relevant “structural space”
coverage of the pilot collection vs. their own in-house
collections
Our initial plan was to apply lters to select for compounds to
target for re-synthesis, but it was clear following consultations
that it is more important to allow any end-user to lter
according to need, so we chose not to apply any lters to the
tangible collection.
The objective in this aspect of the pilot was to lter and
prole the collection against collections assembled and main-
tained externally vs. institution-specic interpretations of
molecule quality. We anticipated that the comparison against
SME and larger company databases across the agrochemical
and pharmaceutical space would be much more informative
than a snapshot against a single company.
Methods
We engaged 15 university Chemistry departments to provide
representative theses: Bradford, Bristol, Bath, Cambridge, Car-
diﬀ, Glasgow, Hudderseld, Imperial, Leeds, Leicester, Lough-
borough, Nottingham, Oxford, Southampton, Strathclyde and
UCL. Where feasible, we divided these into geographical clus-
ters (e.g. Nottingham/Loughborough/Leicester) with a lead
institution (and identied lead academic) within which we
planned to locate one or more “data collectors”; clusters of three
universities had two data collectors assigned. In addition, St
Andrews and Birmingham, via the British Library, provided us
with access to their digital repository and we also selected
theses from these universities.
Our data collectors were recruited within the lead university
and were current or newly graduated chemistry PhDs. Their
brief was to cover their local or cluster of universities and to
target as wide a variety of diﬀerent synthetic theses as possible.
We set up and ran a training and brieng session in February
2014 and the cohort rapidly established a blog site that enabled
them to deal with unforeseen issues collectively and share
experiences and good practice. The data collectors worked to
a common protocol and were managed via weekly Skype
conferences or one-to-one meetings. There was an initial period
associated with “learning the processes” but all data collectors
quickly reached very productive levels.
We sought to include a variety of theses covering diﬀerent
topics to try to maximise diversity of structure, and we only used
published (i.e. openly accessible and non-restricted) theses. To
ensure that contributors could make best use of the theses
available to select from, we undertook to ask permission for
nal release of the complete data collection.
Input forms were provided to key in the thesis level infor-
mation, and then individual structures were pasted in from
Fig. 1 Data entry comprised deposition of thesis information plus
structure information and metadata concerning compound charac-
terisation data plus thesis location. Pre-processing provided an
opportunity for the submitter to check summary information. There
was an opportunity to upload ESI (e.g. Pubmed ID or DOI) at the
conﬁrmation stage; it was also the ﬁnal opportunity for the Submitter
to check and amend the uploaded information. Prior to ﬁnal publi-
cation to the embargoed NCC pilot collection, each entry was
approved by an RSC data curator.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci.
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ChemDraw together with accompanying compound identiers
and data availability ags (see Fig. 1). Once data deposition was
complete (based on InChI), ChemSpider automatically calcu-
lated and added a range of additional properties (e.g. SMILES
string, mol. wt., mol. formula, pKa, c log P etc.) that provided the
basis of a future ltering mechanism. The entry also included
indexing data summarising the analytical characterisation
carried out and reported in the thesis, as well as information
around chirality. A key data entry within ChemSpider was the
bibliographic details of the thesis: e.g. author, supervisor,
publication year, thesis title, university.
During Feb–June 2014, we collected 45 098 individual
structure entries (as above). Duplicates were removed and
where we had an entry for a racemic compound, the individual
enantiomers were generated as unique entries for analysis on
output. Where we had a single enantiomer (or a structure with
up to two undened stereocentres), RSC also generated the
“other” enantiomer and/or diastereoisomers. This step was
taken to maximise the chances of a calculated match in the in
silico screening against protein targets (Goal 3).12
There was a notable variation in the number of theses ob-
tained from each institute (Fig. 2). Quantifying this variation is
further complicated by the fact that the university recorded in
ChemSpider is that of the current or last known institute of the
PhD supervisor (and thus not necessarily the university that
awarded the PhD degree). In turn, this means that the number
of institutes recorded in Fig. 2 is greater than the 15 that
formally partnered this pilot study. Finally, this leads to
a considerable variation in the number of compounds
abstracted from each university and there is little correlation
between the number of theses extracted and the number of
compound records obtained from each department.
At the conclusion of the data entry phase, a total of 45 098
individual chemical structures had been input and expanded to
75 000 unique structure entries on output. Of the 45 098 data
entries,31k (70%) were new structural entities to ChemSpider.
Thesis mining
In parallel to identifying the 15 universities to supply the theses,
and working out the practical details previously described, there
were extensive discussions between the British Library and the
pilot study group, focussing on discoverability, accessibility and
licensing issues, as well as the impact on copyright of text and
data mining activities.
Some universities have already undertaken large scale scan-
ning of PhD theses to convert paper to an electronic format, but if
this type of resource is to have real value, the level of metadata
available that can be used to retrieve more detailed information
needs to be signicantly improved inmany cases. This reects on
another issue, which is the level of consistency between diﬀerent
institutions in terms of how they collate, curate and oﬀer for
dissemination thesis data and metadata, as well as diﬀerent
practices in terms of the licensing and subsequent availability of
the theses. Currently oen only minimal searchable data are
associated with a paper thesis: student name, title, date. Perhaps
department name is included in a catalogue but as a rule, theses
are not searchable by supervisor nor can entries be interrogated
by a standard set of keywords (subject/discipline area and sub-
discipline and other key words etc.). If this issue around meta-
data is not addressed, then the prospect of eﬃciently and cost-
eﬀectively retrieving data (structural data in our case) from
legacy theses becomes almost insurmountable.13 Given that the
development of electronic research archives within universities is
already underway, a recognition of and response to this issue of
inadequate metadata is a matter of urgency. The risk otherwise is
that the electronic variants suﬀer from the same issues of inac-
cessibility (and hurdles to data retrieval) as the current physical
thesis collections.
At the outset, copyright was viewed as another signicant
issue in this area, however there have been some pertinent
changes to UK copyright law in 2014 and it is now feasible to
apply automated tools to extract data without the need for
permissions to be gained, provided that this is done for a non-
commercial use.14 The guidance published by the UK Intellec-
tual Property Oﬃce provides a clearer understanding of the
relationship between copyright, automated data extraction and
commercial exploitation. Having a much-improved under-
standing of these issues, we were able to tackle Goal 4 –
assessment by external bioscience/pharma partners to evaluate
the “uniqueness” and relevant “structural space” coverage of
the pilot collection.
Results
The National Compound Collection (NCC) dataset was evalu-
ated for structural uniqueness via a custom-developed script
Fig. 2 Number of compounds abstracted per institute compared to
the number of theses indexed per institute (institute ordering is the
same).
Chem. Sci. This journal is © The Royal Society of Chemistry 2016
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written by NQuiX (see ESI‡). A number of drug discovery groups
from the pharmaceutical, biotech, academic and not-for-prot/
charity sectors were provided with both the dataset and the
program.
Of these, 9 partners (AZ, Domainex, Dundee, Evotec, GSK,
MRC-T, Pzer, Syngenta and UCB) generated data comparing
the NCC with their in-house compound collections; NQuiX
provided extensive data for the NCC versus marketed drugs,
bioactive compounds from the literature and commercially
available “purchasable” samples (Fig. 3); and both Lilly and the
Structural Genomics Consortium provided feedback on the
value of the dataset using their own methods.
The standardised comparison process measured the novelty
of the compounds in four diﬀerent ways: using two diﬀerent
types of chemical ngerprint (Chemical Hashed Fingerprint
(CFP)15 and Extended Connectivity Fingerprint (ECFP)16),
counting the number of novel Bemis–Murcko structural
frameworks,17 and counting the number of novel ring systems.
The soware used for this work provided a ready means to
fragment molecules into constituent parts but required a rule
set to be dened for the relevant transformations. Using
a simple breakage of bonds between ring atoms and non-ring
atoms does not produce what could be intuitively regarded as
the relevant “ring systems”. Such a procedure would generate
a contiguous group of ring atoms for more complex fused and
joined rings such as steroid frameworks and biaryls but it would
also cleave the carbonyl oxygen from a lactam, for example. In
keeping with a number of other groups,18–20 we felt that atoms
alpha to the ring system should be retained. However, rather
than dealing only with the specic issue of doubly bonded
pendant atoms, we wanted to know the full substitution pattern
around rings since, if novel, these were suggestive of new
options for decoration – and hence chemical diversity – even if
the ring core had itself previously been described. We were less
concerned to know about variation in atom type at the substi-
tution point, so converted them to a generic atom (denoted “A”
for any). In summary, the advantage of including the attach-
ment point into the “ring system” as dened is that this can
Fig. 3 (a) The eﬀect of tighter ﬁltering on comparison of the NCC pilot with a standardised set. As expected, when the loosest criteria are applied,
the greatest number of compounds pass the ﬁlters and the curve plateau is at around 45 000 compounds; the application of the tightest ﬁltering
results in around a plateau at around 5000 ﬁlter passes. (b) The eﬀect of comparing the NCC pilot output to collections of increasing diversity.
The standardised database of Bioactives is both larger and more chemically diverse than the Drugs database; therefore NCC compounds have
a higher probability of being scored similar to a compound in the Bioactives database than in the Drugs database – hence the area under the
curve is greater for the comparison to Bioactives. (c) The comparison of the NCC to the nine companies’ corporate collections. Curves plateau at
diﬀerent levels, reﬂective of diﬀerent deﬁnitions of ﬁlter stringency for “Normal Filtering”. Areas under the curve vary according to the size and
diversity of each organisation’s collection. (d) An example of four organisations that have implemented ﬁlters of very similar stringency. The
diﬀering area under the curve reﬂects each organisation’s diﬀerent size and diversity of corporate collection. In this example, all would beneﬁt,
but the pilot NCC would add value to the diversity of collections in the order 10 > 3 > 7 > 8.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci.
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make otherwise equivalent rings appear very diﬀerent in terms
of important characteristics such as synthetic route, scope for
expansion (i.e. diversity) and t to target.
Whilst the NCC dataset contained just over 75 000 entries in
total, this gure was reduced to 68 000 following structure
regularisation21 and elimination of, for example, isotopically
labelled variants and alternative salt forms. The number of
compounds could (if desired) be further reduced by the appli-
cation of sub-structural and property lters that seek to ensure
“drug-likeness”.
The principle of attempting to improve drug-likeness for
designed molecules in biopharmaceutical science (encompass-
ing aspects which include potency, selectivity, absorption,
distribution, metabolism, excretion and toxicity characteristics)
is nowwell established and interpretations of “quality” have been
published by multiple groups.5,22 Each drug discovery group was
therefore free to impose its own controls over the lters and was
encouraged to use two diﬀering levels: “loose” ltering, appro-
priate for the identication of potential tool molecules, and
“regular” ltering, consistent with more usual Compound
Collection Enhancement/Lead Generation type activities.
The proportion of the 68k unique NCC structures passing the
drug-likeness lters ranged from approximately 5% to 80%
depending on the strictness, yielding between 3k and 55k
compounds for the diversity analysis. On average, 50% of the
structures passed the ltering process (see Fig. 3).
Typically 2k structures (3% of 68k) were found to be very
highly diverse compared to the existing collections (<40% Tani-
moto similarity of CFP). A fair proportion of these look to be
rather small (there is usually no lower bound on MW in the
lters) and some may be appropriate for fragment-based drug
discovery eﬀorts. Other compounds within this subset looked
potentially undesirable, for example, for reasons related to
metabolic stability. These structures have most likely passed the
ltering process because they represent new chemotypes but,
being previously unseen, it is simply that no sub-structural drug-
likeness lter has been generated for them as yet. This is very
much in line with guidance issued by Lilly in their PD2 initiative –
compounds that are too dissimilar to their collection cease to be
drug-like and slip through the lters and are discarded.23,24
Arguably more interesting from a drug discovery standpoint
are the 13k compounds with good diversity (40–60% Tani-
moto similarity of CFP). These compounds – representing
around 18% of the NCC pilot – are quite diﬀerent from those
that are already present in the screening collections but not so
diﬀerent that they cease to be drug-like. Given that the database
contains chemistry in its broadest sense and captures reagents
as well as nal products, this is very encouraging and many
Fig. 4 Good diversity compounds identiﬁed by each company as a percentage of each company’s ﬁlter passes. Companies 4 and 5 have a very
high ﬁltering stringency, and we suspect that their passes are also much smaller in molecular size. The lower molecular size and complexity
makes it harder for the ﬁlter passes to be diverse relative to known compounds.With company 8, the ﬁltering stringency is about average but they
have a collectionwith greater similarity to the NCC and hence fewermolecules with good diversity. Interestingly, by this measure, the similarity of
the comparator set to the NCC is more important than the stringency of deﬁnition. Note that comparing loose or regular ﬁltering yields very
similar numbers of good diversity compounds as a percentage of ﬁlter passes. In this example, the smallest comparison set is the Drugs ﬁle;
unsurprisingly, over 60% of compounds are of good diversity as a percentage of ﬁlter passes. Aside from the already mentioned companies 4, 5
and 8, for the majority of companies, 30–50% of compounds pass ﬁlters and demonstrate good diversity. This sweet spot of diverse, ﬁlter-pass
compounds represents around 18% of the NCC compounds.
Chem. Sci. This journal is © The Royal Society of Chemistry 2016
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drug discovery teams would consider these compounds to be
high value molecules for inclusion in their screening collections
(Fig. 4).
Focussing on rings and frameworks as a methodology for
analysis highlights signicant potential diversity in the drug-
like subset of NCC. In particular, the selection is highly
diverse, with only a very small number of analogues per che-
motype. On average, there were 6726 distinct ring systems of
which only 861 (13%) were already present in screening
collections and 2065 distinct frameworks of which only 742
(36%) were precedented (Fig. 5).
In the foregoing discussion, the results slightly overstate the
novelty of the NCC in comparison to corporate collections.
Some ring systems occur in the NCC that are unsubstituted and
low inmolecular weight; i.e. they are the complete structure, not
a substructure and are therefore classied as reagents. For
many organisations, the corporate compound registry would
contain reagents but these would not be part of the screening
collection due to their reactivity, scope for assay interference
and undesirability as screening hits. We asked our partner
companies to generate comparison data against their screening
collections and so the lower molecular weight entities are less
likely to be present unless represented as part of a fragment-
based set. This nding is also reective of the fact that our
data collectors were encouraged to upload all of the examples
from a thesis’ experimental section, since at the point of upload,
they were in no position to reliably judge what is novel and what
is not. To estimate the overstatement of novelty, the pilot NCC
was compared to the control Bioactives database, using
a regular level of ltering, and 668 from 6385 “novel” ring
systems are unsubstituted. Extrapolation across the data set
would suggest an overstating of novelty of around 10%.
The small number of compounds representing each che-
motype (as well as the fragment-sized scaﬀolds) presents
opportunities for academic and commercial data exploitation.
As an example, computational tools are freely available that can
prospectively focus eﬀorts on those scaﬀolds that have the
potential to target novel lead-like chemical space. Recently,
Nelson and Marsden have developed and launched LLAMA
(http://llama.leeds.ac.uk), an open-access tool that allows the
lead-likeness of scaﬀolds to be assessed. In most cases, the
originators of the thesis chemistry described best understand
the opportunities and weaknesses in the chemistry described
therein; hence they are well placed to interrogate their own
chemistry with design tools such as LLAMA, planning follow-on
chemistry that lls some of the currently sparsely-populated
chemical space. An example would be the potential use of the
NCC in helping to enable synthesis of compounds designed and
evaluated through LLAMA (through close neighbours that
reside within NCC) either to provide insight into synthetic
routes or by diversion of an original idea to a series that has
already been enabled in NCC. Learning from the Joint European
Compound Library initiative, academic/Contract Research
Organisation partnerships are a very eﬃcient way of scaling out
this type of diversity-oriented synthesis.25
Future outlook
On the conclusion of data evaluation, each source university has
been supplied with a le comprising “their” thesis entries and
links to compounds to enable them to take a decision on
whether to make their compounds available in the NCC data
release. In consequence, of the 45 098 pilot compounds
abstracted, 44 430 are available as a CC0 licensed download, as
well as available through ChemSpider. Once compounds are
released to the public, a “take down” policy will operate so that
data are removed if and when a copyright holder objects, which
is in line with industry best practice.26,27
This pilot exercise provided a reference to 45 098
compounds associated with 746 source theses provided by 135
academic supervisors. The analysis carried out with industry
partners illustrates that the output has a signicant level of
novelty compared to both known compounds or to corporate
collections. Additionally the analysis vs. “quality” lters also
illustrates the potential utility of the compounds vs. bio-
pharmaceutical applications.
Following the successful conclusion of the pilot, the pursuit
of a national scale in silico collection based on discoverable
theses that builds on the results of this pilot study merits
serious consideration. In this context, the funding options and
mechanisms for longer term sustainability for this activity and
a role for UK universities need also to be examined. Given the
current emphasis on translational science and assessment of
Fig. 5 (a) Illustrative examples of novel ring systems relative to known
bioactive compounds. (b) Ring system 1 corresponds to two unique
NCC entries 2 and 3. Compound 2 possibly lacks signiﬁcant scope for
decoration; however many users would consider compound 3 to be
more desirable. (c) Examples of frameworks that are novel compared
to known bioactive compounds. 4 is quite simple and we were
surprised that it was classiﬁed as novel; 5 is an example at the opposite
end of the complexity spectrum and probably undesirable to many; 6
is another interesting framework with plenty of scope for elaboration.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci.
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research impact, this is a topic for Research Council consider-
ation and could be seen to be analogous to the block grants
announced in 2012 (ref. 28) by RCUK (to fund article processing
and open access charges), aiding implementation of RCUK
policy on open access to research outputs. A critical component
of such an exercise is the development of a clear picture as to
the numbers of Chemistry legacy PhD theses available to be
extracted, and the cost-benet ratio involved in mining this
likely very signicant number of legacy theses; this is a retro-
spective deposition of structural information and a continuation
(and scaling out) of this pilot study. Two issues that need to be
considered are the fact that many older theses do not have
a graphical representation of the structure within the unstruc-
tured pdf pages of the experimental section; in this context data
extraction from scanned theses could be further compromised
if OCR introduces errors into the generation of chemical names.
Secondly, while there are large diﬀerences in the availability and
accessibility of theses across UK institutions, the copyright
exception would likely not apply if commercial partners are
involved to build sustainability. Taken together, these factors
will dictate that a signicant level of manual interrogation and
intervention will be needed and so in the longer term, the bulk
of data may need to be derived from the forward-looking
pathway i.e. direct data extraction from newly-published
theses (Fig. 6). As distinct from the retrospective pathway, this
can be termed prospective deposition and many of the opportu-
nities and issues for this route have been scoped out in the
previously mentioned dra RCUK Concordat.
The National Chemical Database Service (NCDS) is an
EPSRC-funded service provided by the Royal Society of Chem-
istry to all students and other members of UK academic insti-
tutions.29 This online platform currently provides access to
state-of-the-art chemistry databases and tools for the benet of
the chemical research community, with a data repository for UK
chemical research data also under development. Ultimately, the
development of a data repository could facilitate “forward-
looking” deposition of published PhD theses. In other words, it
will enable future PhD students or their university to deposit
primary and (critically) metadata under embargo, allowing the
work that has been done to be discoverable in a more controlled
and timely manner.
Recognising that open access to research data carries
a signicant cost, thought also needs to be given to the long-
term sustainability of a database of discoverable thesis experi-
mental details. In direct parallel to the consideration of open
data within the HEI sector, more Early Discovery collaborative
agreements are being put in place between large pharmaceu-
tical companies and partners, where the shared goals of the
partners are to explore a greater diversity of compounds against
diverse biological targets. This in turn creates the opportunity
for an NCC to borrow from the concepts that have already been
developed in thinking more broadly about how the metadata
around compound ownership and origin impacts their ability to
use information and maintain an audit trail.30 Open innovation
partnerships encompass many diﬀerent models31 and a search-
able thesis collection should also develop in ways that aim to
maximise researcher impact through increased collaboration,
technology transfer and commercialisation whilst simulta-
neously lowering barriers to collaboration and licensing
through reduction in the administrative thicket of patents,
CDAs and MTAs.32,33
The question of physical samples relating to the pilot dataset
was outside the scope of this project, but in the longer term the
broader chemistry community (universities, end-users, CROs,
funders) has an opportunity to engage around the case to
translate the tangible in silico database to a physical collection
and this should recognise the legacy and forward-looking
components of an in silico-focussed activity.
Conclusions
The National Compound Collection pilot study set out to ach-
ieve a series of key goals to demonstrate the level of “added
value” around under-exploited chemical structure data that is
available using published PhD theses as an “open access”
(published and openly-available) resource.
We believe that this pilot study, in achieving the tasks we set
ourselves, has demonstrated clearly that PhD theses, indepen-
dent of the primary chemical literature, provide a highly valu-
able source of new chemical structure information. A thesis, as
a published document, oﬀers access to a quality controlled
experimental procedure and by linking ChemSpider to the
thesis detail, the postgraduate student author (and copyright
holder) is credited more fully for the work that they have done.
We recognise where there remains work to be done; identi-
fying those “unknown unknowns” was also a function of the
pilot. Copyright issues may also link to any future use of the
data collection and there is a clear need to coordinate the ways
in which universities and the British Library convert paper-
based theses to a usable and readily searchable electronic
resource that harnesses the “added value” that is available.
Fig. 6 A reappraisal of data entry. A retrospective data entry route will
involve a mixture of manual processing and Optical Character
Recognition (OCR). The quality and breadth of metadata that are
captured will be critical to the success of this approach. Prior to this
exercise, much of the metadata captured was at best variable and at
worst inadequate. If this is not rectiﬁed, the collections created will
lack resilience for data mining. Prospective data entry presents
diﬀerent issues. Technically, data entry will be best accomplished
using an Electronic Lab Notebook (ELN) or via an Application Program
Interface (API). Key success factors here will be security and ﬂexibility
of embargo which will in turn give research groups the opportunity to
record the output of strategic programmes of work across several
theses to then allow structure release, once the work is considered
suﬃciently complete.
Chem. Sci. This journal is © The Royal Society of Chemistry 2016
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We used a legacy (i.e. already published) set of theses and see
real value in further legacy mining as well as engaging with the
broader (and beyond UK) academic community to harvest new
theses into a data collection as they are produced and cleared
for publication.34
As has been noted elsewhere, we are moving towards a more
open world, in which organisations need to collaborate in order
to thrive.35,36 The old, linear paradigm where each player’s posi-
tion was clearly dened has evolved into a dynamic network of
non-traditional partnerships in which compounds, data, exper-
tise and knowledge are shared.37,38 The development of a reposi-
tory that makes a signicant volume of publicly-funded research
openly-available will become increasingly valuable in an envi-
ronment where the roles of industry, academia, charities and
research funders in innovation are increasingly overlapping.
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